<DOC>
	<DOC>NCT02656303</DOC>
	<brief_summary>This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304</brief_summary>
	<brief_title>An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Prior treatment in clinical trial UTXTGR304 Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Patients refractory to ublituximab + TGR1202 Transformation of CLL to aggressive NonHodgkin's Lymphoma (NHL) (Richter's transformation)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>